Navigation Links
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
Date:11/21/2007

SOUTH SAN FRANCISCO, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host a conference call with simultaneous webcast to discuss the results of its Phase 2 clinical study of R788, a novel, oral Syk kinase inhibitor, in patients with Immune Thrombocytopenic Purpura (ITP) on Tuesday, December 4, 2007 at 4:30pm E.S.T. Participating on the call will be Rigel senior management and the principal investigator on the study, James B. Bussel, M.D., director of the Platelet Research and Treatment program at the Phyllis and David Komansky Center for Children's Health and NewYork-Presbyterian Hospital/Weill Cornell Medical Center and professor of pediatrics in obstetrics and gynecology and in medicine at the Weill Cornell Medical College. In addition, Rigel will be presenting a poster on R788 in ITP at the ASH meeting on December 8, 2007, from 9:00a.m. - 7:30p.m., in Atlanta, GA.

Conference Call Details

To access the live call, please dial 866-831-6267 (domestic) or 617-213-8857 (international) 10 minutes prior to the start time and use the passcode 14390209. A replay of the call will be available at approximately 3:30p.m. PST on December 4, 2007 until December 11, 2007. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 91472601.

The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary. A replay of the conference call will be available on Rigel's website, in webcast and podcast formats, approximately 2 hours after the call.

Further information on ITP and R788 in ITP is available at Rigel's website: http://www.rigel.com/rigel/ITP.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the potential efficacy of Rigel's product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "indicates," "promising," "expects," "anticipates" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, as well as other risks detailed from time to time in Rigel's SEC reports, including its Form 10-Q for the quarter ended September 30, 2007. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Raul Rodriguez

Phone: 650.624.1302

Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.

Phone: 650.430.3777

Email: susan@alchemyemail.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Rigel Announces Third Quarter 2007 Financial Results
2. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
3. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
6. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the ... Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, on ... donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch ...
(Date:2/23/2017)... ... ... The 89th Academy Awards will be celebrated this weekend, which means it’s ... Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the shoddiest ... for American Progress (CAP), for its report, Lessons From State Performance on NAEP: Why ...
(Date:2/23/2017)... Chapel Hill, NC (PRWEB) , ... February 23, 2017 , ... ... the Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter ... in 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at 10075 ... Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... who have earned high ratings and superior patient reviews from multiple credible sources. , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Research and Markets has announced the ... Strategies - 2016" report to their offering. ... The latest research Autism Spectrum ... data and benchmarks in the global Autism Spectrum Disorder market. ... What are the key drugs marketed for Autism Spectrum Disorder and ...
(Date:2/23/2017)... , Feb. 23, 2017 ITL Limited, ( ASX: ... excellent results for the half year ended 31 December 2016 compared ... Growth Update" presentation can be viewed here . ... (Dec 2015: $1.04m; up 104%) Earnings per share ... Revenue of $17.5m (Dec 2015: $15.7m; up 11%) ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has ... and Strategies - 2016" report to their offering. ... The latest research Oesophageal ... data and benchmarks in the global Oesophageal Cancer market. ... What are the key drugs marketed for Oesophageal Cancer and their ...
Breaking Medicine Technology: